Loading Please wait, logging in.
Join ALFA Member Login RSS Feed
Tagline Image
Bookmark and Share  

Antipsychotics Beneficial For Some Individuals With Alzheimer’s

A new study suggests that people with Alzheimer’s on the drug risperidone, an antipsychotic drug often prescribed as the brand name Risperdal, may be better off continuing to take the drug if they have not experienced negative side effects.

Because of the potential side effects, risperidone is only recommended to be prescribed for three to six months. After that point, a written explanation is required to continue the drug. A study, published in the New England Journal of Medicine and funded by the National Institutes of Health, investigated the effects of discontinuing the medication among individuals who had seen improvements as a result of the drug. Researchers prescribed risperidone to individuals with Alzheimer’s disease who showed signs of agitation and aggression. After 16 weeks, researchers put half of the individuals who did well on the drug on a placebo. The other half continued the treatment. The study found that those on the placebo were twice as likely to have their symptoms return. The rate of side effects and death were equal among the two groups.

Researchers warned that antipsychotics can carry the risk of serious side effects and should not be used on all individuals with Alzheimer’s disease, but discontinuing medication that has achieved benefits is not always the right choice. "One must be cautious about discontinuing the medication,” said study author Dr. D.P. Devanand, director of the division of geriatric psychiatry at Columbia Psychiatry and the New York State Psychiatric Institute in New York City.  “If a person does well on it and there are not too many side effects, maybe they should stay on it for a while and be monitored closely."

For more information, read the article: Some With Alzheimer's Better Off Staying on Antipsychotics: Study  Or, read the full study: Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease.

 
Suggested Articles:

12/8/2016
Clinical Quality and Quality Care Delivery, Federal Agency Activity, Legislation, News, Public Policy, Research
On December 7, the Senate voted 94-5 to approve the 21st Century Cures Act bill. The bill seeks to expedite the process of getting new drugs and medi...
12/6/2016
Dementia and Alzheimer’s disease has replaced heart disease as the leading cause of death in England and Wales, making up 11.6 percent of all register...
12/6/2016
Clinical Quality and Quality Care Delivery, Facts and Figures, Health and Wellness, Medication Management, News
Staffing shortages and rising prescription drug costs are two key challenges health care executives will face in 2017, according to a new survey.
12/6/2016
Researchers found beta amyloid deposits, which are associated with Alzheimer’s disease, accumulated in cardiac tissue of people with Alzheimer’s.
12/1/2016
Clinical Quality and Quality Care Delivery, Facts and Figures, Falls Prevention, Federal Agency Activity, Managed Risk, News, Research, Risk Management
Falls are the leading cause of injuries among adults age 65 and older and the Centers for Disease Control and Prevention has released the latest data,...
12/1/2016
Clinical Quality and Quality Care Delivery, Community Awareness and Education, Federal Agency Activity, Long Term Care Insurance, News
The Administration for Community Living has released an updated Frequently Asked Questions page about the Long-Term Care Ombudsman Program.
11/29/2016
Engage, Managed Risk, News
An initial focus of the partnership will be on developing research related to human capital benefits benchmarking in senior living and risk management...
11/21/2016
Advocacy, Clinical Quality and Quality Care Delivery, Community Awareness and Education, End of Life, Federal Agency Activity, Managed Risk, Medication Management, News, Public Policy
Colorado became the sixth state to approve language allowing terminally ill patients to end their own lives thanks to approximately two-thirds of vote...
11/21/2016
“Mini brains” grown in a lab and small enough to fit on the head of a pin are helping researchers better understand how the brain works and in turn, b...
11/10/2016
Federal Agency Activity, Medication Management, Medication Technology & Informatics, News, Science and Technology, Technology Infrastructure
The Social Security Administration has launched a new health information technology initiative with the Department of Veterans Affairs enabling all So...
   
10/23/2012


Additional Resources